Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.54 |
| ▸ | ATIC | P31939 | 2/20 | 0.45 |
| ▸ | TYMS | P04818 | 3/20 | 0.45 |
| ▸ | GART | P22102 | 1/20 | 0.45 |
| ▸ | FPGS | Q05932 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463689 | 0.89 | DHFR (0.63) | DHFRATICTYMSGART | |
| SCHEMBL10065545 | 0.85 | TYMS (0.60) | DHFRATICTYMSGART | |
| SCHEMBL463708 | 0.83 | DHFR (0.58) | DHFRATICTYMSGARTFPGS | |
| SCHEMBL408871 | 0.80 | DHFR (0.72) | DHFRATICTYMSGARTFPGS | |
| SCHEMBL410474 | 0.78 | DHFR (0.76) | DHFRATICTYMSGARTFPGS | |
| SCHEMBL18709164 | 0.76 | KDM4E (0.47) | DHFRTYMS | |
| SCHEMBL10065664 | 0.76 | TYMS (0.51) | DHFRATICTYMSGART | |
| Dideazafolate SCHEMBL10036542 | 0.76 | DHFR (0.90) | DHFRATICTYMSGART | |
| Dideazafolate SCHEMBL30799321 | 0.76 | DHFR (0.90) | DHFRATICTYMSGART | |
| SCHEMBL24413587 | 0.75 | DHFR (0.76) | DHFRATICTYMSGARTFPGS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396040-B1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET SA (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-8986650-B2 | Complex folate-NOTA-Ga68 | GUERBET (FR) | 2015-03-24 | — | — | US | disclosed |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | GUERBET (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | DHFR 408/4885ATIC 988/4885TYMS 2924/4885 |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | FOLR1, FOLR2, DHFR | DHFR 3/4885ATIC 70/4885TYMS 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.